Trial Profile
A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2020
Price :
$35
*
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2020 Status changed from active, no longer recruiting to completed.
- 05 Jul 2020 Results published in the Gynecologic Oncology
- 13 Feb 2018 According to an Advaxis media release, based on the 12-month survival rates observed in this trial, the company has submitted a conditional Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, recurrent or metastatic carcinoma of the cervix (PRmCC).